• Innovative Therapies
    for Children with Cancer in Europe
  • Contact us


Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology

Promotor Name : Boehringer Ingelheim

Investigator Name : B. GEOERGER

Trial registered on NCT02372006